Diabetes Control & Complications Trial (DCCT)

From Aaushi
Jump to navigation Jump to search

Introduction

Demonstrates that the risks for development & progression of retinopathy, nephropathy & neuropathy with diabetes mellitus are:

  • increasing levels of hemoglobin A1c
  • reduced by 35-75% with intensive treatment targeted at near-normal glycemia

Methods

Adults & adolescents with type 1 diabetes mellitus

Ref 2c followed 175 of 195 adolescents for an additional 4 years. In this extended study nephropathy & retinopathy were diminished in the intensive treatment group; however, HgbA1c was not different.

Notes

  • Epidemiology of Diabetes Interventions & Complications (EDIC) study is a long-term follow-up of DCCT.[4]

Results:

More general terms

References

  1. Medical Knowledge Self Assessment Program (MKSAP) 11, American College of Physicians, Philadelphia 1998
  2. Journal Watch 22(3):20, 2002 Diabetes Control & Complications Trial (DCCT)/ Epidemiology of Diabetes Interventions & Complications (EDIC) Research Group a) N Engl J Med 329:977, 1993 b) J Pediatri 125:228, 1994 c) J Pediatr 139:804, 2001
  3. Diabetes Control and Complications Trial (DCCT) http://diabetes.niddk.nih.gov/dm/pubs/control/index.htm
  4. 4.0 4.1 Nathan DM et al, Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med. 2005 Dec 22;353(25):2643-53. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16371630
    Cefalu WT Glycemic control and cardiovascular disease - should we reasses clinical goals N Engl J Med. 2005 Dec 22;353(25):2707-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16371637